NEW
YORK, July 9, 2024 /PRNewswire/ -- Lindus
Health, the "anti-CRO" running radically faster, more reliable
clinical trials for life science pioneers, and Aktiia, the
pioneering blood pressure intelligence startup offering
non-invasive and cuffless continuous blood pressure monitoring,
have announced the launch of their clinical trial to evaluate user
satisfaction with Aktiia's optical blood pressure monitoring (OBPM)
device in hypertensive individuals.
Hypertension, or high blood pressure, is estimated to affect
over 1.3 billion adults globally, and is the leading cause of heart
disease, stroke, kidney disease, and many other diseases. Devices
that continuously monitor blood pressure can offer valuable
insights into hypertension severity, treatment efficacy, and
fluctuations related to daily activity, lifestyle, and sleep
patterns.
This study will examine user experience with Aktiia's
non-invasive, cuffless OPBM device. The device, worn as a bracelet,
measures blood pressure continuously using optical sensors,
offering a more convenient alternative to traditional blood
pressure cuffs. In addition to measuring satisfaction with the
device, the trial will also observe the evolution of participants'
blood pressure over the study period and correlate this data with
sociodemographic, lifestyle, and health factors.
Lindus Health and Aktiia will enroll 7,500 participants with
known hypertension in this 12-week clinical trial. Lindus Health
will provide end-to-end study management, including protocol
development, regulatory submissions, recruitment, monitoring, and
data management. They will utilize their in-house virtual site and
digital marketing capabilities for patient recruitment through
digital advertising as well as primary care screening and patient
community outreach. A dedicated study website will be developed
with relevant trial information and integrated with Lindus Health's
proprietary eClinical platform, Citrus™, to enable candidates to
seamlessly complete pre-screening and eConsent.
"Lindus Health is incredibly humbled to be collaborating on the
Aktiia trial, where we'll have the ability to provide thousands of
individuals with continuous visibility on their blood pressure on a
continuous basis," said Michael
Young, co-founder at Lindus Health. "Hypertension greatly
burdens both patients and healthcare systems and there is an
evident need for technologies that effectively help individuals
manage chronic diseases while seamlessly integrating with their
everyday lives."
"Aktiia's technology gives individuals greater autonomy to
better manage their health," said Dr. Jay
Shah, Chief Medical Officer at Aktiia. "Our device and
smartphone application allow patients and providers to understand
their blood pressure patterns and changes in real-time, making it
easier to pinpoint causes for fluctuations. We're excited and proud
to be working with Lindus Health to deliver blood pressure
intelligence to patients with hypertension to help them better
manage their condition."
Favorable outcomes pertaining to user experience will underscore
the value in developing wearable devices to continuously monitor,
manage, and prevent chronic diseases that are both accurate and
comfortable.
About Lindus Health
Lindus Health is an anti-CRO running radically faster and more
reliable trials for life science pioneers – bringing
ground-breaking treatments to patients more quickly. This is
achieved through a commercial model that aligns incentives
(fixed-priced quotes per study, with milestone-based payments), a
world-class clinical operations team with its unique software
platform, and access to over 30 million Electronic Health
Records.
Clinical trials are the biggest bottleneck to advances in
healthcare. Lindus Health removes this constraint by handling the
end-to-end execution of clinical studies, including design, patient
recruitment, clinical data capture, monitoring and project
management.
To date, Lindus Health has delivered more than 90 trials across
the US, UK and Europe to tackle a
range of conditions, including diabetes, asthma, acne, social
anxiety, major depressive disorder, hypertension, chronic fatigue
syndrome and insomnia. The company has raised over $24M from investors including Peter Thiel, CREANDUM, Firstminute Capital,
Presight Capital, Seedcamp, Hambro Perks, Amino Collective and
Calm/Storm.
About Aktiia
Founded in Switzerland in
May 2018, Aktiia was created out of a
passion to develop the best
products for diagnosing and treating hypertension. Founders Drs.
Mattia Bertschi (CEO) and Josep Solà
(CTO) spent 15 years at the prestigious Swiss research institute
CSEM, deciphering the language of the heart and blood vessels to
deepen our understanding of blood pressure - the world's most
common risk factor of death and disease.
Today, Aktiia's diverse team of over 50 extraordinary
individuals is transforming years of innovative research into a
global healthcare solution, offering the most complete and
intuitive blood pressure monitoring and management tools on the
market.
https://aktiia.com
Media contact: press@aktiia.com
Lindus Health Media Contact:
Jodi Perkins
Amendola for Lindus Health
jperkins@acmarketingpr.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lindus-health-and-aktiia-to-launch-observational-clinical-trial-for-aktiias-optical-blood-pressure-monitoring-device-302191705.html
SOURCE Lindus Health